. . . . . "S&T TWOC Project - version 4" . "S&T TWOC version 3" . "2"^^ . "2023-07-20T09:47:13.618094"^^ . . . "for COVID-19 therapy" . "(203, 220)" . "considered" . "498" . "other antibiotics like azithromycin , ivermectin , eravacycline , valrubicin , streptomycin , nitazoxanide , teicoplanin , caspofungin , and colistin ; and other agents like hydroxychloroquine , chloroquine , tocilizumab , camostat , nafamostat , carfilzomib , interferon , aprepitant , and dexamethasone" . "(203, 220)" . "Results Repurposing of drugs from different pharmacological groups including antivirals like remdesivir, lopinavir, ritonavir, arbidol, oseltamivir, penciclovir, favipiravir, ganciclovir, and ribavirin; other antibiotics like azithromycin, ivermectin, eravacycline, valrubicin, streptomycin, nitazoxanide, teicoplanin, caspofungin, and colistin; and other agents like hydroxychloroquine, chloroquine, tocilizumab, camostat, nafamostat, carfilzomib, interferon, aprepitant, and dexamethasone can be considered for COVID-19 therapy." . "8j41d0a3" . "8j41d0a3-TRIPLE-ABSTRACT-2" . "other antibiotics" . "covid-19" . "RSA" . "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" . "ZR/R6hSS3AyM5XAOF+m8cwWSD5l5BHyPV/rM4CcfGjg/rQHNQULN9uU6gqpJkjYzfJP79H+qS20VaWMclGJrsC6s/91+C5bemxOsXVnVdV+GsWiCJZAPItWFmVh8XhzaYDlfFkCqCVYGUsNJvkoXUdXjGl32zdynePKAq5V1CdwKO94462sysvUcV9CMoqH/Jg/9+rlibb49eIIMWUcP57tMU3oz7hOF/8voMEV3Q0Euyl2/h5wS6W6mLnEuzy3o/lwRVouA8zo9cvF6VLW1kcI0R1zdzmVeg2UZshTx8szKR2fu3h+bvpHGl51EHH82iYhRaHtE26YbvgIWhIVRfvrnp/HMEANOnvhu6cxuSW7eUlE5lY+1kEEd58hxTr8XZXFOiTJbwPXYhq+ZL3ImWAsyHugMuZ9V8xgUcPz3/zV96eWi/jcgCHDzTvRhCTD1HdJ4g6fxmesvqFbgXytEuSP25a2Dj2G1CcBzlNs0WUjvOSj94qIipnlJ5B6TU9TV" . . .